key: cord-0953890-3q27f39q authors: Shi, H.; Zuo, Y.; Gandhi, A. A.; Sule, G.; Yalavarthi, S.; Gockman, K.; Madison, J. A.; Zuo, M.; Shi, Y.; Knight, J. S.; Kanthi, Y. title: Endothelial cell-activating antibodies in COVID-19 date: 2021-01-20 journal: medRxiv : the preprint server for health sciences DOI: 10.1101/2021.01.18.21250041 sha: f5397cfb732250beb8d3f5f8de63950e668a8c6a doc_id: 953890 cord_uid: 3q27f39q Patients with coronavirus disease 19 (COVID-19) are at high risk for fibrin-based occlusion of vascular beds of all sizes. Although endothelial cell activation has regularly been described as part of the COVID-19 thrombo-inflammatory storm, the upstream mediators of this activation have yet to be fully elucidated. Here, we began by pursuing the hypothesis that circulating factors such as neutrophil extracellular trap (NET) remnants, D-dimer, or C-reactive protein might predict the COVID-19 serum samples (n=118) that most robustly activated cultured endothelial cells. Indeed, we found modest correlations between serum NET remnants (cell-free DNA, myeloperoxidase-DNA complexes, citrullinated histone H3) and upregulation of surface E-selectin, VCAM-1, and ICAM-1 on endothelial cells. However, a more robust predictor of the ability of COVID-19 serum to activate endothelial cells was the presence of circulating antiphospholipid antibodies, specifically anticardiolipin IgG and IgM and anti-phosphatidlyserine/prothrombin (anti-PS/PT) IgG and IgM. Depletion of total IgG from anticardiolipin-high and anti-PS/PT-high samples markedly restrained upregulation of E-selectin, VCAM-1, and ICAM-1. At the same time, supplementation of control serum with patient IgG was sufficient to trigger endothelial cell activation. These data are the first to reveal that patient antibodies are a driver of endothelial cell activation and add important context regarding thrombo-inflammatory effects of COVID-19 autoantibodies in severe COVID-19. Derangements in coagulation correlate with COVID-19 severity (1, 2) . Indeed, there are now myriad reports demonstrating the high risk of both venous thromboembolism (3, 4) and arterial thrombosis including strokes and myocardial infarctions (4, 5) in patients with Furthermore, histopathology of autopsy brain and lung specimens from patients with severe disease demonstrate dysfunctional endothelium and fibrin-based occlusion of small vessels (6) (7) (8) (9) . There are several (possibly synergistic) mechanisms by which SARS-CoV-2 infection may result in macrovascular and microvascular thrombosis (10) including a cytokine storm that activates leukocytes, endothelium, and platelets; direct activation of various cells by viral infection; and high levels of intravascular neutrophil extracellular traps (NETs) (11, 12) . The latter are inflammatory cell remnants that amplify thrombosis (13) (14) (15) (16) . In recent months, there have been a number of descriptions of what appears to be a priori autoantibody formation in individuals with moderate-to-severe COVID-19. One example replicated by multiple groups is the detection of antiphospholipid antibodies (aPL Abs), which mediate antiphospholipid syndrome (APS) in the general population (17) . In APS, patients form durable autoantibodies to phospholipids and phospholipid-binding proteins such as prothrombin and beta-2-glycoprotein I. These autoantibodies then engage cell surfaces, where they activate endothelial cells, platelets, and neutrophils (18, 19) and thereby tip the blood-endothelium interface toward thrombosis. Case reports and case series have suggested a link between COVID-19 disease severity, circulating aPL Abs, and thrombotic events (20) (21) (22) (23) (24) (25) . While viral infections have long been known to trigger transient aPL Abs (26) (27) (28) (29) , mechanisms by which these short-lived antibodies may be pathogenic have never been characterized. To this end, our group recently found that COVID-19 IgG fractions enriched for aPL Abs potently activate neutrophils in vitro, while also potentiating thrombosis when injected into mice (30) . Beyond aPL Abs, autoantibodies against the type I interferon response (31, 32) and platelets (33) have been described in moderate-to-severe COVID-19, with both demonstrating potentially important functional properties in vitro. At the same time, the circulating B cell compartment of COVID-19 appears reminiscent of the autoimmune disease lupus whereby naïve B cells rapidly take an extrafollicular route to becoming antibody-producing cells (34, 35) , and in doing so bypass the normal tolerance checkpoints against autoimmunity provided by the germinal center. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Here, we were interested in the extent to which circulating NET remnants might be an important activator of endothelial cells. We also necessarily turned our attention to aPL Abs as markers of COVID-19 serum with strong endothelial cell activating-potential. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 35% were receiving mechanical ventilation, while 74% required supplemental oxygen support of any kind. Serum from the COVID-19 patients was diluted to 2.5% in culture media and then added to early-passage human umbilical vein endothelial cells (HUVEC) (Figure 1A) . The expression of surface activation markers was determined after 6 hours by a custom in-cell ELISA compatible with the Biosafety Level-3 facility in which the experiments were performed ( Figure 1A) . As compared with serum samples from 40 healthy controls, the COVID-19 samples triggered an activated endothelial cell phenotype as evidenced by markedly increased surface expression of the leukocyte adhesion molecules E-selectin ( Figure 1B) , VCAM-1 ( Figure 1C) , and ICAM-1 ( Figure 1D ). Taken together, these data indicate that COVID-19 serum contains factors capable of activating endothelial cells. Association of NET remnants with the endothelial cell-activating potential of COVID-19 serum. As discussed above, work by our group and many others have demonstrated that circulating NET remnants associate with both COVID-19 severity and coagulation system activation (11, 36) . Given that NETs are known activators of endothelial cells (37) (38) (39) , we asked whether NET remnants might predict the ability of a particular COVID-19 serum sample to upregulate surface E-selectin, VCAM-1, and ICAM-1. Specifically, we measured NETs in serum via quantification of cell-free DNA, MPO-DNA complexes, and citrullinated histone H3 (Cit-H3) ( Table 1) . Serum MPO-DNA complexes demonstrated a modest correlation with surface expression of both VCAM-1 (r=0.256, p<0.01) and ICAM-1 (r=0.277, p<0.01). Cell-free DNA and Cit-H3 both correlated with VCAM-1 only (r=0.237, p<0.05 and r=0.224, p<0.05, respectively) ( Table 1) . Beyond these relatively specific markers of NETs, we also sought correlations with general markers of thrombo-inflammation including C-reactive protein, D-dimer, and neutrophil calprotectin. Of the three markers, only neutrophil calprotectin demonstrated modest correlations with expression of the three endothelial cell surface markers (r=0.187-0.203, p<0.05) ( Table 1) . Taken together, these data demonstrate modest correlations between NETs, thrombo-inflammation in general, and the ability of COVID-19 serum to activate endothelial cells. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Given that we recently demonstrated that aPL Abs isolated from patients with COVID-19 had the ability to stimulate neutrophils to release NETs (30), we reasoned that COVID-19 derived aPL Abs might also activate endothelial cells. We focused on the IgG and IgM isotypes of two types of aPL Abs (anticardiolipin and anti-PS/PT) that accounted for the majority of positive tests in our recent study (30) . Interestingly, we detected strong and consistent correlations between all four antibodies and the three markers of endothelial cell activation (E-selectin, VCAM-1, and ICAM-1) ( Table 1 ). The only correlation that was not statistically significant was between anti-PS/PT IgM and VCAM-1 (r=0.115, p>0.05) ( Table 1 ). In summary, while we noted modest correlations between serum NET remnants and upregulation of E-selectin, VCAM-1, and ICAM-1, much stronger correlations were seen between various aPL Abs and endothelial cell activation as measured by surface expression of the three adhesion molecules. While aPL Abs robustly correlated with the endothelial cell-activating potential of COVID-19 serum, we reasoned that there might be another co-circulating factor in serum that was actually driving endothelial cell activation. We therefore sought to prove or disprove whether IgG fractions from COVID-19 patients could directly activate HUVEC. To this end, we pooled serum from five COVID-19 patients with high aCL IgG and separately five patients with high anti-PS/PT IgG activity. We then subjected the serum to either mock or IgG depletion. As compared with mock depletion, IgG depletion completely mitigated the ability of both of the pooled samples to upregulate endothelial cell Eselectin (Figure 2A) , VCAM-1 ( Figure 2B ) and ICAM-1 ( Figure 2C ). Upregulation was not though affected by pre-treatment with a pan-Fc receptor blocker, suggesting Fc independence of the antibody-mediated activation (Supplementary Figure 1) . We next purified a small quantity of IgG from each pool, and then spiked it into control serum that had been depleted of its own IgG. The COVID-19 IgG-supplemented control serum now demonstrated an ability to increase expression of surface ICAM-1 ( Figure 2D ). Taken together, these data indicate that the presence of aPL Abs strongly associates with COVID-19 IgG samples that are able to activate endothelial cells. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.18.21250041 doi: medRxiv preprint Here, we report for the first time that serum from COVID-19 patients activates cultured endothelial cells to express surface adhesion molecules with a known role in thrombosis, namely E-selectin, VCAM-1, and ICAM-1. Furthermore, we found that for at least a subset of serum samples, this activation could be completely mitigated by depleting the samples of IgG. Prothrombotic aPL Abs associated strongly with these phenotypes suggesting a new mechanism by which these autoantibodies may perpetuate thrombo-inflammation in COVID-19. The role of aPL Abs in activating endothelial cells has been demonstrated both in vitro and in vivo (40) . For example, IgG fractions from APS patients have long been known to activate HUVEC, as reflected by increased monocyte adherence and expression of adhesion molecules (41) (similar to what we demonstrated here for COVID -19) . In APS, aPL Abs may further promote endothelial dysfunction by antagonizing eNOS via the apoER2 receptor (42, 43) . Downstream of aPL Ab engagement of the endothelial cell surface, various intracellular messengers including MyD88, NF-κB, and AP-1 may participate in endothelial cell activation (44, 45) , although exact mechanisms remain to be fully elucidated (46) . Beyond canonical aPL Abs, the concept of "anti-endothelial cell antibodies" has also garnered some attention in lupus and APS (47) . These autoantibodies (antigen specificity unclear) have been reported to enhance leukocyte adhesion and promote thrombosis through interference with clearance of dying cells (48) or cooperation between Fc gamma receptor IIa and CXCR1/2 (49) . Whether such antibodies may exist in association with aPL Abs in COVID-19 is an interesting question deserving of further research. In addition to our findings (30), a number of other groups have also provided evidence for pathogenic autoantibodies in COVID-19 (31, 33, 50) . For example, a recent study detected autoantibodies against type I IFNs (13.7%) in patients with life-threatening COVID-19 (31) , and provided evidence that these autoantibodies have the ability to neutralize interferons ex vivo. Another small study suggested that IgG from COVID-19 patients had the ability to induce platelet phosphatidylserine externalization and apoptosis through interactions with Fc gamma receptor IIa, which may be associated with thromboembolic complications in COVID-19 patients (33) . An interesting study used a high-throughput autoantibody discovery technique to screen a cohort of COVID-19 patients for autoantibodies against 2,770 extracellular and secreted proteins (51) . The authors found a tendency for autoantibodies to be directed against immunomodulatory proteins including cytokines, chemokines, complement components, and All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. This study has some limitations including reliance on serum samples discarded by the clinical laboratory, a lack of a direct readout of thrombosis given aggressive anticoagulation used at our center early in the pandemic, and a so far incomplete understanding of mechanisms by which aPL Ab-associated IgG fractions activate endothelial cells. However, given the urgency of COVID-19 research, we believe these weaknesses are counterbalanced by the relatively large sample size and the heretofore unknown discovery of endothelial cell-activating antibodies in COVID-19 serum. Indeed, these data also put the diffuse organ involvement of COVID-19 into context, where a non-specific humoral response to the illness may disrupt the normally quiescent endothelium and potentiate vascular inflammation. As we await the definitive immunologic solutions that will hopefully end the pandemic, these findings give further context to the complex interplay between SARS-CoV-2 infection, the human immune system, and COVID-19 severity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. 10,000 cells/well were seeded into 0.2% gelatin-coated 96-well tissue culture plates the day before experiments. The following day, HUVEC were cultured with 2.5% human serum or IgG at a concentration of 100 μg/ml at 37°C in a humidified atmosphere of 5% CO2. All experiments were performed using HUVEC of passage 6 or fewer. IgG depletion from serum. IgG was purified from COVID-19 and control serum with protein G Agarose beads (Pierce). Briefly, 800 μl of protein G agarose beads were washed at least 10 times by PBS. Then, 200 μl of serum was added and incubated with the beads at 4°C overnight. The supernatant was collected after spinning the tube at 2500xg for 5 minutes. The supernatant was the IgG depleted serum. The same volume of serum was incubated without beads under the same conditions as a mock control. Depletion was confirmed by Coomassie-stained gels. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. quantified similarly to what has been previously described (58). This protocol used several reagents from the Cell Death Detection ELISA kit (Roche). First, a high-binding EIA/RIA 96-well plate (Costar) was coated overnight at 4ºC with anti-human myeloperoxidase antibody (Bio-Rad 0400-0002), diluted to a concentration of 1 µg/ml in coating buffer (Cell Death kit). The plate All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.18.21250041 doi: medRxiv preprint was washed two times with wash buffer (0.05% Tween 20 in PBS), and then blocked with 4% bovine serum albumin in PBS (supplemented with 0.05% Tween 20) for 2 hours at room temperature. The plate was again washed five times, before incubating for 90 minutes at room temperature with 10% serum or plasma in the aforementioned blocking buffer (without Tween 20). The plate was washed five times, and then incubated for 90 minutes at room temperature with 10x anti-DNA antibody (HRP-conjugated; from the Cell Death kit) diluted 1:100 in blocking buffer. After five more washes, the plate was developed with 3,3',5,5'-Tetramethylbenzidine Statistical analysis. Normally-distributed data were analyzed by two-sided t test and skewed data were analyzed by Mann-Whitney test when two groups were analyzed. Correlations were tested by Spearman's correlation coefficient. Data analysis was with GraphPad Prism software version 8. Statistical significance was defined as p<0.05. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Cit-H3=citrullinated histone H3; CRP=C-reactive protein *p<0.05, **p<0.01, ***p<0.001, and **** p<0.0001 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. D, IgG (100ug/ml) was purified from the pooled samples referenced in A-C, and then spiked into control serum that had been depleted of IgG. Activation of HUVEC was determined after culture for 6 hours as defined by surface expression of ICAM-1. Groups were compared by 1-way ANOVA with correction for multiple comparisons by Tukey's test; **p<0.01. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.18.21250041 doi: medRxiv preprint Shi et al. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. minutes before the addition of 2.5% pooled COVID serum. Activation of HUVEC was determined after culture for 6 hours as defined by surface expression of ICAM-1. The experiment was repeated on 3 different days, and bars represent mean and standard deviation. Groups were compared by one-way ANOVA with correction for multiple comparisons by Dunnett's test; ns=not significant. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.18.21250041 doi: medRxiv preprint Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans Microvascular Injury in the Brains of Patients with Covid-19 COVID-19-associated coagulopathy: An exploration of mechanisms Neutrophil extracellular traps in COVID-19 Neutrophil calprotectin identifies severe pulmonary disease in COVID-19 Targeting potential drivers of COVID-19: Neutrophil extracellular traps Vascular occlusion by neutrophil extracellular traps in COVID-19 Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome Immunothrombotic Dysregulation in COVID-19 Pneumonia is Associated with Respiratory Failure and Coagulopathy. Circulation Treatment of thrombotic antiphospholipid syndrome in adults and children Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome Antiphospholipid syndrome: a clinical perspective Antiphospholipid antibodies in patients with COVID-19: A relevant observation? Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients? Brief Report: Anti-phospholipid antibodies in critically ill patients with Coronavirus Disease 2019 (COVID-19). Arthritis Rheumatol Prevalence, specificity, and clinical association of anti-phospholipid antibodies in COVID-19 patients: are the antibodies really guilty? medRxiv Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis Primary', 'secondary' and other variants of the antiphospholipid syndrome Systematic review of case reports of antiphospholipid syndrome following infection COVID-19) Infection Associated With Antiphospholipid Antibodies and Four-Extremity Deep Vein thrombosis in a Previously Healthy Female Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19 Autoantibodies against type I IFNs in patients with life-threatening COVID-19 Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Antibody-induced procoagulant platelets in severe COVID-19 infection Elevated SARS-CoV-2 Antibodies Distinguish Severe Disease in Early COVID-19 Infection Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19 Neutrophil extracellular traps and thrombosis in COVID-19 Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death Neutrophil Extracellular Traps Drive Endothelial-to-Mesenchymal Transition Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo Activation of cultured vascular endothelial cells by antiphospholipid antibodies Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via beta2GPI and apoER2 Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies Anti-endothelial cell antibodies in primary antiphospholipid syndrome and SLE: patterns of reactivity with membrane antigens on microvascular and umbilical venous cell membranes Anti-endothelial antibodies interfere in apoptotic cell clearance and promote thrombosis in patients with antiphospholipid syndrome Antiendothelial cell antibodies mediate enhanced leukocyte adhesion to cytokine-activated endothelial cells through a novel mechanism requiring cooperation between Fc{gamma}RIIa and CXCR1/2 Broadly-targeted autoreactivity is common in severe SARS-CoV-2 Infection. medRxiv Diverse Functional Autoantibodies in Patients with Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients Functional diversification of IgGs through Fc glycosylation Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity Proinflammatory IgG Fc structures in patients with severe COVID-19 APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking HS, YZ, JSK, and YK conceived the study and analyzed data. All authors participated in writing the manuscript and gave approval before submission.